What Alesse-28 Treats: Main Uses and Benefits

Alesse-28 is generally utilized as a reliable method for preventing pregnancy, offering systemic contraceptive support for women of reproductive potential. This primary indication, alongside its therapeutic role in managing certain conditions, constitutes an important domain of use. This class of medication is sometimes used to address related symptoms in certain patients. The medication is commonly applied to address symptoms of disruptive cyclical patterns, including painful menstrual cramps (dysmenorrhea), heavy menstrual blood loss (menorrhagia), and irregular cycles. It is also relevant for hormonally-driven dermatological issues such as moderate acne vulgaris.

This symptomatic management is relevant when supportive relief is appropriate for conditions characterized by periods of heightened symptoms related to the menstrual cycle. The medication provides support that helps ease the overall symptom load and helps maintain a sense of stability through predictable cycle regularity. This application is associated with symptomatic relief across key domains, assisting with supporting functional stability.

Quick Fact: Relief for Cyclical Discomfort and Acne

The medication is commonly used to help manage the symptomatic burden of conditions where multiple symptoms occur together, such as painful cramps, heavy bleeding, and moderate acne. This application supports the patient during difficult episodes by easing distress and may assist with managing the appearance of blemishes, contributing to easing day-to-day comfort during symptomatic periods.

Regulatory References

1. NIH MedlinePlus overview of oral contraceptives

Eligibility Map: Official Regulatory Information

The eligibility for Alesse-28 is strictly defined by regulatory documents, which establish clear restrictions and absolute contraindications primarily related to cardiovascular, oncologic, and hepatic risk.

Category	Regulatory Status
Allowed Population	Post-menarcheal females of reproductive potential.
Age Restriction	Contraindicated in females over 35 years of age who smoke cigarettes.
Pregnancy/Lactation	Contraindicated during known or suspected pregnancy. Not generally recommended while breastfeeding.

Contraindicated Populations (Must Not Use):

The medicine is prohibited for individuals with a high risk of arterial or venous thrombotic diseases. This includes a current or history of thromboembolic disorders (e.g., DVT, PE, Stroke) or hereditary blood-clotting disorders. Use is also strictly prohibited with known or suspected breast cancer or other estrogen-dependent tumors, active liver disease, or liver tumors. It is also contraindicated in patients with uncontrolled hypertension or Diabetes Mellitus with vascular involvement. The FDA label also prohibits use with Hepatitis C drug combinations containing Ombitasvir, Paritaprevir, and Ritonavir, with or without Dasabuvir.

Special Use Restrictions:

Use is not indicated for postmenopausal women. For non-lactating females postpartum, initiation is restricted to no earlier than four weeks after delivery due to elevated thromboembolic risk.

Interactions with other medicines and products

Alesse-28 contains the hormones ethinyl estradiol and levonorgestrel, and its effectiveness or safety can be altered by co-administration with other substances. The profile is primarily defined by pharmacokinetic interactions that change the concentration of these hormones in the body.

Clinically Significant Interactions

Interaction Type	Examples of Interacting Substances
Exposure-Reducing (Potential decrease in contraceptive efficacy)	CYP3A4 Enzyme Inducers (e.g., rifampin, phenytoin, St. John's wort), certain antibiotics (e.g., griseofulvin).
Exposure-Increasing (Potential increase in hormone levels or co-administered drug levels)	CYP3A Inhibitors (e.g., fluconazole, itraconazole), Atorvastatin, Ascorbic Acid, Acetaminophen.
Alteration of Co-administered Drug Levels	Lamotrigine (levels decreased by Alesse-28), Tizanidine (levels increased by Alesse-28).

Interaction Restrictions

Contraindicated Combinations: Alesse-28 must not be used concurrently with Hepatitis C Virus (HCV) drug regimens containing ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, due to the risk of severe liver enzyme elevations (ALT).

Timing Requirement: The bile acid sequestrant Colesevelam must be administered at least 4 hours after taking Alesse-28, as this substance can otherwise reduce the absorption of the hormone components.

How Alesse-28 Works: Mechanism of Action

The mechanism of action for Alesse-28 relies on the synergistic effects of its hormonal components, levonorgestrel (progestin) and ethinyl estradiol (estrogen), to influence three primary mechanistic domains.

HPO Axis Suppression: Inhibiting Ovulation

This domain details the drug's primary action, involving the suppression of the Hypothalamic-Pituitary-Ovarian (HPO) axis). The synthetic hormones induce a negative feedback loop on the pituitary gland, inhibiting the release of key signaling molecules (FSH and LH) necessary to stimulate the ovary, which results in the core physiological effect of anovulation (inhibition of ovum release).

Cervical and Endometrial Modulation: Physical Barriers

This domain focuses on the peripheral effects, where the progestin component acts on localized receptor systems in the cervix and uterus. It increases the viscosity of the cervical mucus, creating a thick, physical barrier that restricts sperm motility, and simultaneously induces atrophy of the uterine lining, which alters the environment needed for potential implantation.

Hormonal Dynamics: Regulation of Systemic Steroids

This domain covers the molecular influence on systemic protein synthesis and hormonal balance. The estrogen component upregulates the production of Sex Hormone-Binding Globulin (SHBG) in the liver. SHBG binds to circulating steroids, altering the concentration of biologically active androgens.

Official Administration Guidelines

Alesse-28 is administered through the oral route, requiring the patient to swallow one tablet daily. The medicine is provided in a 28-day regimen that dictates a continuous, cyclical pattern of use.

Dosing Schedule and Timing

Instruction	Detail
Standard Adult Dose	One tablet taken daily for 28 consecutive days.
Cycle Composition	The dose consists of 21 active tablets (containing 0.1 mg levonorgestrel and 0.02 mg ethinyl estradiol) followed by 7 inactive, hormone-free tablets.
Fixed Timing	The tablet must be taken at the same time each day at intervals not exceeding 24 hours to maximize consistent exposure.
Context	Taking the tablet after the evening meal or at bedtime may assist with proper use by mitigating potential stomach upset.

Procedural Constraints and Specific Use

Adherence to a precise start date and sequencing is a core component of the protocol. The regimen can be started on the first day of menstruation (Day 1 Start) or the first Sunday following the start of menstruation (Sunday Start). If the Sunday Start or any initiation later than Day 1 is chosen, a nonhormonal back-up method of contraception must be used for the first seven consecutive days of active tablet administration. Use of the product is established for women of reproductive age; it is not indicated for use before menarche or for postmenopausal women.

The overall use protocol is defined by this continuous 28-day cycle, which structures the long-term, daily administration of the product.

Research Evidence / Overview of Studies for Alesse-28

---

Research Evidence for Pregnancy Prevention

The primary research supporting research on this product has its foundation in large-scale studies and trials that evaluated the potential of this formulation in the context of pregnancy prevention. Initial regulatory authorization was based on pivotal, open-label, single-arm clinical trials. These trials were primarily applied in studies examining patient-reported experiences and outcomes related to cycle numbers of exposure. The main outcome monitored in these studies was evaluated in women of reproductive potential by tracking the reported rate of pregnancy.

Systematic reviews and large observational studies contribute to the broader evidence landscape by exploring the patterns of the combined oral contraceptive (COC) class. Findings describe patterns observed in the studies that are aligned with the medication's mechanism of action related to contraception. The evidence base is substantial for the entire pharmacological class, yet comparative evidence is lacking in head-to-head trials against all other specific COC options. The long-term effects are not fully established through dedicated, extended-duration randomized controlled trials specifically for this low-dose formulation.

---

Research Evidence for Moderate Acne Vulgaris

The research base for this product includes dedicated clinical trials that evaluated its activity in the context of moderate facial acne. These trials include randomized, double-blind, placebo-controlled designs (RCTs). These studies research examined outcomes related to inflammatory and non-inflammatory lesions. Researchers studies monitored changes in lesion counts and used a Clinician Global Assessment (CGA) score. These measurements research highlights changes measured during the study period in both the active and placebo groups.

Follow-up durations were limited, with the primary evidence derived from six treatment cycles. Data for certain groups remain insufficient, as the studies results apply only to the populations studied, focusing predominantly on moderate facial acne. Therefore, the research provides limited insight into outcomes for individuals with more severe or non-facial acne.

Common questions about Alesse-28 (FAQ)

---

Q: How long does Alesse-28 stay in your system after stopping?

Regulatory documents describe how the hormones are processed by the body. The time it takes for the active components to be eliminated can be estimated using their half-lives: approximately 36 hours for levonorgestrel (progestin) and 18 hours for ethinyl estradiol (estrogen) at steady state.

---

Q: Do studies suggest that Alesse-28 can help with acne?

Official documentation indicates that the product is authorized for the treatment of moderate acne vulgaris in women who also desire contraception. The research base includes clinical trials that evaluated its activity for this specific official use.

---

Q: Can Alesse-28 be used for purposes other than contraception?

Official indications for this medicine include both the prevention of pregnancy (conception control) and the treatment of moderate acne vulgaris in eligible patients. The authorized use is defined by the specific official authorizations for the product.

---

Q: Can Alesse-28 be taken while breastfeeding is described as an option?

Official warnings advise against the use of this medicine while breastfeeding. This caution is based on the fact that the hormones can pass into breast milk and may potentially slow down the production of breast milk.

---

Q: What is the role of ethinyl estradiol in Alesse-28?

The mechanism of action involves the synthetic estrogen component, ethinyl estradiol, working alongside the progestin. Ethinyl estradiol supports the drug's action by helping to regulate the menstrual cycle and is described in official documents as influencing systemic protein synthesis, such as Sex Hormone-Binding Globulin (SHBG).

---

Q: How quickly can Alesse-28 start preventing pregnancy?

The time to effectiveness depends on the start method. If administration begins on the first day of the menstrual cycle (Day 1 Start), it is associated with the commencement of effectiveness immediately. However, if started later (such as a Sunday Start), official guidance requires using a nonhormonal back-up method for the first seven consecutive days of active tablet administration.

---

Q: How long do side effects from Alesse-28 usually last when first starting?

When first starting a combined oral contraceptive like this one, initial side effects are common. Regulatory information suggests that effects such as nausea, vomiting, and breakthrough bleeding are often observed to lessen or clear up within the first three months of continuous use as the body adjusts to the hormones.

---

Q: Is it common to have lighter or shorter periods on Alesse-28?

The expected bleeding that occurs during the placebo (inactive pill) week is known as withdrawal bleeding. This bleeding is commonly described as often being milder and lighter in flow than a person's typical menstrual period, reflecting the drug's action on the uterine lining.

---

Q: Do many people experience spotting when they first start taking Alesse-28?

Breakthrough bleeding or spotting is listed as a common side effect in official documents, especially when the medicine is first started. This type of bleeding is typically transient (temporary) according to the product documentation.

---

Q: Is it normal to miss a period while using Alesse-28?

Missing a scheduled withdrawal bleed or experiencing an unusual change in bleeding patterns is a change that official safety information indicates may require evaluation. It may be an indication of pregnancy or other changes.

---

Q: Can stomach issues like nausea happen when starting Alesse-28?

Nausea and vomiting are classified as common adverse reactions, especially when a person is first starting the medicine. Official guidelines note that taking the tablet after the evening meal or at bedtime may assist with proper use and reduce potential stomach upset.

---

Q: Is weight gain a common side effect described for Alesse-28?

Changes in body weight are noted in regulatory safety information as a documented side effect of this class of medicine. Weight gain is noted in regulatory safety information as a reported effect.

---

Q: Are there official descriptions of how Alesse-28 affects libido?

Changes in sexual interest or libido (sex drive) are noted in the safety profile. However, it is an effect for which the precise incidence rate is not known according to regulatory documentation.

---

Q: Is it normal to feel bloated when starting Alesse-28?

Bloating and cramping in the stomach area are effects that are documented in the regulatory safety information. These are often temporary as the body adjusts to the hormonal components.

---

Q: What kind of impact is Alesse-28 described to have on cholesterol levels?

Regulatory documentation describes a potential for changes in serum lipid levels. This includes a possible uncommon increase in triglycerides, a condition known as hypertriglyceridemia, which is noted among metabolic side effects.

---

Q: What if I vomit after taking Alesse-28?

If vomiting occurs shortly after taking the tablet, the regulatory guidance for this class of medicine often addresses the need to use a nonhormonal back-up method of contraception.

---

Q: What are the chances of pregnancy described in research when using Alesse-28 correctly?

Research indicates that with perfect use (meaning the medicine is taken exactly as directed without fail), the reported effectiveness for preventing pregnancy is described as approximately 99%. With typical use, the failure rate is reported to be between 7% and 9%.

---

Q: Does Alesse-28 offer protection against sexually transmitted infections?

No. Official information confirms that hormonal contraceptives, including this medicine, do not protect against sexually transmitted infections (STIs), such as HIV, hepatitis B, or gonorrhea.

---

Q: Are there any age limits described for starting Alesse-28?

The medicine is authorized for use in women of reproductive age. However, official labeling confirms that it is not indicated for use before menarche (the start of menstruation).

How to Store and Dispose of Alesse-28

The official labeling mandates specific conditions for storing Alesse-28 tablets to maintain their stability.

Required Storage and Protection

The medication must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted temperature excursions up to 30 C. The tablets must be protected from both light and excess moisture, and must be kept in the original container. Storage environments like bathrooms, which are prone to excessive heat and humidity, should be avoided. Consistent with regulatory safety requirements, Alesse-28 must be kept out of the sight and reach of children and pets.

Disposal Instructions

Unused or expired Alesse-28 should be disposed of through a dedicated drug take-back program or by returning it to a pharmacy, as this is the preferred method established by regulatory authorities. The product is not approved to be flushed down the toilet or sink.